

## S 2912

Trickett Wendler Right to Try Act of 2016

**Congress:** 114 (2015–2017, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** May 10, 2016

**Current Status:** Committee on Homeland Security and Governmental Affairs. Hearings held.

**Latest Action:** Committee on Homeland Security and Governmental Affairs. Hearings held. (Sep 22, 2016)

**Official Text:** <https://www.congress.gov/bill/114th-congress/senate-bill/2912>

### Sponsor

---

**Name:** Sen. Johnson, Ron [R-WI]

**Party:** Republican • **State:** WI • **Chamber:** Senate

**Cosponsors** (43 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blunt, Roy [R-MO]	R · MO		May 18, 2016
Sen. Flake, Jeff [R-AZ]	R · AZ		May 18, 2016
Sen. Hatch, Orrin G. [R-UT]	R · UT		May 18, 2016
Sen. Inhofe, James M. [R-OK]	R · OK		May 18, 2016
Sen. Isakson, Johnny [R-GA]	R · GA		May 18, 2016
Sen. McCain, John [R-AZ]	R · AZ		May 18, 2016
Sen. Murkowski, Lisa [R-AK]	R · AK		May 18, 2016
Sen. Perdue, David [R-GA]	R · GA		May 18, 2016
Sen. Capito, Shelley Moore [R-WV]	R · WV		May 19, 2016
Sen. Corker, Bob [R-TN]	R · TN		May 19, 2016
Sen. Cotton, Tom [R-AR]	R · AR		May 19, 2016
Sen. Graham, Lindsey [R-SC]	R · SC		May 19, 2016
Sen. Grassley, Chuck [R-IA]	R · IA		May 19, 2016
Sen. Rubio, Marco [R-FL]	R · FL		May 19, 2016
Sen. Sessions, Jeff [R-AL]	R · AL		May 19, 2016
Sen. Tillis, Thomas [R-NC]	R · NC		May 19, 2016
Sen. Risch, James E. [R-ID]	R · ID		May 23, 2016
Sen. Boozman, John [R-AR]	R · AR		Jun 7, 2016
Sen. Toomey, Patrick [R-PA]	R · PA		Jun 8, 2016
Sen. Vitter, David [R-LA]	R · LA		Jun 8, 2016
Sen. Barrasso, John [R-WY]	R · WY		Jun 9, 2016
Sen. Coats, Daniel [R-IN]	R · IN		Jun 9, 2016
Sen. Sullivan, Dan [R-AK]	R · AK		Jun 14, 2016
Sen. Cruz, Ted [R-TX]	R · TX		Jun 16, 2016
Sen. Enzi, Michael B. [R-WY]	R · WY		Jul 6, 2016
Sen. Wicker, Roger F. [R-MS]	R · MS		Jul 7, 2016
Sen. Daines, Steve [R-MT]	R · MT		Jul 13, 2016
Sen. Cochran, Thad [R-MS]	R · MS		Jul 14, 2016
Sen. Crapo, Mike [R-ID]	R · ID		Jul 14, 2016
Sen. Heller, Dean [R-NV]	R · NV		Jul 14, 2016
Sen. Hoeven, John [R-ND]	R · ND		Jul 14, 2016
Sen. Lankford, James [R-OK]	R · OK		Jul 14, 2016
Sen. Manchin, Joe, III [D-WV]	D · WV		Jul 14, 2016
Sen. McConnell, Mitch [R-KY]	R · KY		Jul 14, 2016
Sen. Moran, Jerry [R-KS]	R · KS		Jul 14, 2016
Sen. Roberts, Pat [R-KS]	R · KS		Jul 14, 2016
Sen. Rounds, Mike [R-SD]	R · SD		Jul 14, 2016
Sen. Shelby, Richard C. [R-AL]	R · AL		Jul 14, 2016
Sen. Donnelly, Joe [D-IN]	D · IN		Sep 6, 2016
Sen. Gardner, Cory [R-CO]	R · CO		Sep 21, 2016
Sen. Paul, Rand [R-KY]	R · KY		Sep 22, 2016

Cosponsor	Party / State	Role	Date Joined
Sen. Sasse, Ben [R-NE]	R · NE		Sep 26, 2016
Sen. King, Angus S., Jr. [I-ME]	I · ME		Nov 15, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 10, 2016
Homeland Security and Governmental Affairs Committee	Senate	Hearings By (full committee)	Sep 22, 2016

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
114 HR 3012	Related bill	<b>Jul 29, 2015:</b> Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

## Summary (as of May 10, 2016)

### Trickett Wendler Right to Try Act of 2016

This bill bars the federal government from prohibiting or restricting the production, manufacture, distribution, prescribing, or dispensing of an experimental drug, biological product, or device that is: (1) intended to treat a patient who has been diagnosed with a terminal illness; and (2) authorized by, and in accordance with, state law. The federal government may not restrict the possession or use of such a treatment by a patient certified by a physician as having exhausted all other treatment options.

A producer, manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.

The outcome of production, manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.

The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.

Not later than 30 days after enactment of this bill, and every 30 days thereafter until implementation is complete, the FDA must report on its progress in implementing a streamlined application process for compassionate use of experimental drugs and biological products.

## Actions Timeline

- **Sep 22, 2016:** Committee on Homeland Security and Governmental Affairs. Hearings held.
- **May 10, 2016:** Introduced in Senate
- **May 10, 2016:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.